Dissemin is shutting down on January 1st, 2025

Published in

F1000Research, F1000Research, (8), p. 1692, 2019

DOI: 10.12688/f1000research.19500.1

Links

Tools

Export citation

Search in Google Scholar

Developing a phosphodiesterase-5 inhibitor assay to detect counterfeit drugs containing phosphodiesterase-5 inhibitors using spectrophotometry

Journal article published in 2019 by Aziemah Azizi, Asrin Tengah, Mark I. R. Petalcorin ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

Background: Phosphodiesterase-5 inhibitors (PDE5i) are the first line of drugs used for the treatment of erectile dysfunction. PDE5i inhibits the activities of phosphodiesterase-5 (PDE5) found in corpus cavernosum reducing production of guanosine monophosphate (GMP) that results in vasodilation of blood vessels thereby prolonging penile erection. Various counterfeit drugs adulterated with unknown levels of PDE5i pose a danger with reported undesirable adverse effects on patients. Methods: We developed an assay to detect counterfeit drugs containing PDE5i using spectrophotometry based on a colour change of malachite green from blue to green when exposed to inorganic phosphate (Pi) measured at 630 nm. Initially, a standard graph of a known Pi concentration was established ranging from 0 to 20 µM followed by a dual biochemical reaction system of converting GMP from cGMP by PDE5, generating Pi from the first reaction’s product by calf intestinal alkaline phosphatase (CIAP), and then measuring Pi using an equation derived from the generated standard curve. Dilutions of CX1A, a counterfeit drug sample adulterated with the PDE5i sildenafil, were prepared via ultrasonication and filtration for assay testing and evaluation. Results: Sil was detected from the two separate samples comprised of low and high dilutions of CX1A quantified as 0.673% and 0.407%, respectively, based on a standard curve of pure sildenafil established from 0.1 nM to 300 µM. Conclusions: This PDE5i assay that we developed has the potential to become an alternative analytical method for detecting PDE5i showing comparable results when evaluated using HPLC.